Filing Flows › Health Care › Utah Medical Products (UTMD)

Utah Medical Products (UTMD) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Utah Medical Products (UTMD) Q2 2026 earnings results →

Q2 2026 Revenue down 14% year over year to $8.5M · 31¢ of every $1 of revenue kept as net profit · operating margin 31.1%

Utah Medical Products made $8.5M in Q2 2026 (-14% Y/Y): Gynecology/Electrosurgery/Urology $4.3M, Neonatal $1.9M, Blood Pressure Monitoring and Accessories $1.3M. Operating margin 31.1%, net earnings $2.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.

Revenue$8.5M

Year over year-14%

Operating margin31.1%

Net earnings$2.7M

Operating cash flow$1.4M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $8.5M in Q2 2026, down 14% year over year and down 2% from the previous quarter. Gynecology/Electrosurgery/Urology was the largest line at 50% of revenue.

Gross margin was 55.8%, down 0.4 points from Q2 2025. Operating profit was $2.6M, a 31.1% margin (down 1.1 points year over year). Operating expenses fell 12% while revenue fell 14%. The fastest-growing cost line was Research & development (+14%). Net earnings were $2.7M, down 12% year over year. The effective tax rate was 18.3%.

Operating cash flow was $1.4M (down 52% year over year), 51% of net earnings. Non-cash charges added back $226K of depreciation and amortization and $72K of share-based compensation. Working capital and other items used $1.6M. Capital expenditures of $134K left free cash flow of $1.2M.

Quarterly history

Quarter	Form	Filed	Revenue	Y/Y	Op. margin	Net earnings	Op. cash flow
Q2 2026	10-Q	Aug 12, 2026	$8.5M	-14%	31.1%	$2.7M	$1.4M
Q1 2026	10-Q	May 12, 2026	$8.7M	-10%	29.4%	$2.6M	$3.1M
Q4 2025	10-K	Mar 27, 2026	$9.0M	-1%	27.0%	$2.6M	$3.5M
Q3 2025	10-Q	Nov 14, 2025	$9.8M	-2%	26.6%	$2.6M	$3.9M
Q2 2025	10-Q	Aug 12, 2025	$10.0M	-4%	32.1%	$3.0M	$2.9M
Q1 2025	10-Q	May 15, 2025	$9.7M	-14%	32.5%	$3.0M	$4.5M
Q4 2024	10-K	Mar 26, 2025	$9.2M	-26%	32.0%	$2.9M	$2.9M

Charts

Latest (Q2 2026): Y/Y -14%, Q/Q -2%.

From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.

Latest (Q2 2026): Net income $2.7M, Operating cash flow $1.4M.

-11.8% since FY2020: buybacks shrank the count.

Surgical & Medical Instruments & Apparatus; dot size is quarterly revenue; dashed lines are the industry's medians.